CN1903174A - Clotrimazole gel, and its prepn. method - Google Patents

Clotrimazole gel, and its prepn. method Download PDF

Info

Publication number
CN1903174A
CN1903174A CN 200610109674 CN200610109674A CN1903174A CN 1903174 A CN1903174 A CN 1903174A CN 200610109674 CN200610109674 CN 200610109674 CN 200610109674 A CN200610109674 A CN 200610109674A CN 1903174 A CN1903174 A CN 1903174A
Authority
CN
China
Prior art keywords
gel
clotrimazole
stirred
weighing
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200610109674
Other languages
Chinese (zh)
Other versions
CN100446753C (en
Inventor
王锦刚
蒋海松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Kexin Jurun Pharmaceutical Technology Co ltd
Original Assignee
Beijing Kexin Bicheng Medicine Technology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Kexin Bicheng Medicine Technology Development Co Ltd filed Critical Beijing Kexin Bicheng Medicine Technology Development Co Ltd
Priority to CNB2006101096740A priority Critical patent/CN100446753C/en
Publication of CN1903174A publication Critical patent/CN1903174A/en
Application granted granted Critical
Publication of CN100446753C publication Critical patent/CN100446753C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

A mycosporin gel with high percutaneous absorptivity and stability and its preparing process are disclosed.

Description

Clotrimazole gel and preparation method thereof
Technical field
The present invention relates to a kind of clotrimazole gel preparation and preparation method thereof.
Background technology
(Clotrimazole is to be applied to clinical broad-spectrum antifungal medicine the earliest clotrimazole) to clotrimazole.Be applied to the topical treatment of skin monilial infection at present, as tinea corporis, tinea unguium, tinea pedis, tinea versicolor etc.; The mucosa monilial infection infects as lip, oropharynx, anus, pudendum, between referring to; Vaginitis due to vaginal candida infects, and tinea manus and pedis, auditory meatus and vaginomycosis.Also effective to trichomonal vaginitis.Metabolism is slow in vivo for it, and toxicity is low, good effect.
In 95 editions pharmacopeia, the preparation of clotrimazole has suppository, tablet, medicine membrane of oral cavity, ointment, solution; In ministry standard, the preparation of clotrimazole has Mycoporin vaginal effervescent tablet (WS-1001-(HD-0097)-2002), clotrimazole spray (WS-1001-(HD-0231)-2002), Mycoporin vaginal sheet (WS-1001-(HD-1204)-2002).Disclose a kind of liniment of clotrimazole among the Chinese patent CN1053546A, be mainly used in external.
But when clotrimazole is being used for gynecological, during by the vagina topical, vaginal suppository storage inconvenience requires protecting below 30 ℃, uses at some high temperature severe cold areas to be subjected to certain restriction.And comprise other vaginal preparation of vaginal suppository, as fast disintegrating tablet, effervescent tablet, capsule, suppository, foam, ointment, membrane, ubiquity easily comes off from tract, the tract inner membrance is had zest, is difficult to shortcomings such as long-time storage-stable.In order better to improve patient's adaptability, should on the prescription basis of clotrimazole bolt, carry out modified form to it, address these problems.Simultaneously, existing only have a kind of dosage form of clotrimazole bolt to go on the market, and dosage form is single, can not satisfy the medication demand of vast female patient.
Gel is a kind of new formulation that grows up for meeting clinical needs in recent years, it is that the medical high-molecular additive (as carbomer, Carboxymethyl cellulose sodium, polyvinylpyrrolidone, polyvinyl alcohol etc.) that utilizes some new punishment is made gel with medicine, improve medicine local concentration, the release of prolong drug or the purpose of diffusion process thereby reach, have than other dosage form bioavailability height, good stability, the characteristics that untoward reaction is few.With medicine dissolution or be dispersed in and be gel in the gel, it can the long period and the site of action tight adhesion, and better biocompatibility is arranged, and method for making is simple, uses comfortable." Chinese pharmacopoeia 2000 editions has defined gel in two notes on the use: " gel is meant the latex glop or the semi-solid preparation of homogeneous, suspendible or emulsion-type that medicine and the adjuvant that can form gel are made." in modern pharmacy, be slow release, the controlled release form of substrate with the gel; obtained comprehensive research as gastric retention controlled release system, gel matrix tablet, exterior-applied gel etc.; the medicine that is applicable to the gel delivery system has hydrophilic medicament, hydrophobic drug, acidic drug, cationic drug, macromolecular drug, cell tissue etc.; can be from the oral cavity, number of ways administration such as nasal cavity, eye mucosa, gastrointestinal mucosal, vagina, rectum, skin; Chinese medicine gel generally mostly is percutaneous or mucosa delivery, is usually used in aspects such as anti-inflammatory and antalgic, antiviral, pain relieving at present.
But in the gel dosage form, also there are some problems,, usually need to use to promote penetrating agent, as azone for example in order to promote the osmotic absorption of drug administration position to medicine.And existing report azone causes it to make cell membrane function produce irreversibility and changes owing to similar with cell membrane constituent on its chemical constitution.And use too much promotion penetrating agent also can cause release inhomogeneous.Have zest to local mucous membrane for some medicines when drug level is too high in addition, this can greatly reduce patient's adaptability.Stability during the depositing of gel also is the problem that needs solve in addition.
Therefore, for clotrimazole, in order to solve the problem that exists in existing vaginal preparation such as the suppository, though it can be made gel according to conventional thinking, but still need on choice of base, pay performing creative labour, make that clotrimazole gel curative effect on the basis that addresses the above problem is reliable, the patient uses comfortable.
Summary of the invention
The objective of the invention is to overcome the deficiency of prior art, a kind of scalable, good effect that has is provided, the Empecid of nonirritant, compliance advantages of higher, the standard of improving the quality of products simultaneously further satisfies and ensures the medication demand of vast female patient.
Another object of the present invention provides the preparation method of described clotrimazole gel.
Purpose of the present invention can take following method to realize: a kind of clotrimazole gel is characterized in that it comprises clotrimazole and pharmaceutically acceptable gel substrate.
By weight: clotrimazole 3-5% substrate 0.1-15%
Its formula optimization is:
By weight: clotrimazole 5% substrate 10.4%
Described pharmaceutically acceptable gel substrate is following one or more: aqueous gel substrate such as water, glycerol, propylene glycol, cellulose derivative (as methylcellulose, sodium carboxymethyl cellulose etc.), carbomer and alginate, tragacanth, pectin, gelatin, xanthan gum, agar; Non-cellulosic polysaccharide such as chitin, ethene polymers, acrylic resin, polyvinyl alcohol and carbopol etc.; Oil-base gel agent such as liquid paraffin and polyoxyethylene or fatty oil colloid silicon or wrong soap, zinc soap.
Preferred gel substrate is the mixed-matrix of carbomer and glycerol.
If desired, gel of the present invention stabilizing agents such as adding wetting agent, antiseptic, pH value regulator, and additives that promote skin, mucosa absorption.Wetting agent preferably glycerine wherein.The pH value regulator is selected from sodium hydroxide, sodium bicarbonate, sodium carbonate, potassium hydroxide, hydrochloric acid, sulphuric acid, nitric acid, phosphoric acid, triethanolamine etc.Preferred triethanolamine.Antiseptic is selected from benzyl alcohol, methyl hydroxybenzoate.Ethyl hydroxybenzoate, propyl hydroxybenzoate, phenol, chlorobutanol, thimerosal etc.Preferred ethyl hydroxybenzoate.
The preparation method of clotrimazole gel of the present invention is as follows:
(1) distilled water boiling sterilization takes by weighing ethyl hydroxybenzoate 1.5g, is dissolved in the 2100ml hot water (80 ℃), puts and is chilled to 40 ℃, and is standby;
(2) get carbomer 12g in addition, gradation is spread in the above-mentioned solution, is stirred to be uniformly dispersed, and leaves standstill 2h, and is standby;
(3) take by weighing triethanolamine 15g, slowly add in the above-mentioned solution with distilled water (420ml) dilution back; Add glycerol again, be stirred to translucent homogeneous system, the white gel of having leisure;
(4) take by weighing clotrimazole fine powder 150g, evenly spread in the blank gel, be stirred to homogeneous system;
(5) gel is sub-packed in the vaginal administration device, promptly.
Institute's referenced patents document and non-patent literature all are hereby incorporated by with its full content among the application.
The present invention is clotrimazole arbitrarily, all can with pharmaceutically acceptable acid reaction, form corresponding salt.Preferred and the salifiable example of mineral acid shape comprises and formed salt such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid.Preferably with the salifiable example of organic acid institute shape comprise and formed salt such as formic acid, acetic acid, trichloroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, P-toluene sulfonic acide.Comprise and formed salt such as arginine, lysine, ornithine with the formed salt of basic amino acid that preferably the example of the salt of preferred and acidic amino acid institute property comprises formed salt such as glutamic acid, aspartic acid.
The present invention adopts through the preparation technology who optimizes, and determines the rational proportion of principal agent and adjuvant, improves curative effect of medication; Adopt gel technology, utilize gel and site of action closely to stick, have the characteristics of better bioadhesive, the increase medicine contacts with site of action, improves the curative effect of medicine; Adopt vagina administration, the onset piece.The clotrimazole gel preparation transdermal absorption factor height that adopts the present invention to make, steady quality, curative effect is reliable.
To more be expressly understood purpose of the present invention, characteristics and other advantage by the detailed description of carrying out, but they do not attempt in office where face limits the scope of the invention below in conjunction with embodiment.
Describe when of the present invention when the reference specific embodiments, it is evident that those skilled in the art without departing from the spirit and scope of the present invention down, will carry out multiple variation and modification to these embodiments.
Embodiment
One, the selection of gel substrate
The quality that the main investigation index of studying for medicament gelling agent is exactly its transdermal performance.Select suitable substrate to help to improve the Transdermal absorption ability of medicine.The application adopts clotrimazole as index, absorb method of testing (as Wu Wanying etc. with reference to conventional transdermal test in vitro, the research of Radix Sophorae Flavescentis total alkaloids percutaneous rate under the different pH value, the Chinese medicine journal, 1999 (2), 61-62), the Transdermal absorption of clotrimazole in the clotrimazole gel of selecting different gel substrate for use is tested comparison.
1. grouping and administration
60 of Wister male rats, body weight 255.8 ± 29.6 is divided into 6 groups at random by body weight.With the clotrimazole bolt respectively with carbomer 934, Acritamer 940, Carbopol 941, methylcellulose, sodium carboxymethyl cellulose, cross linked sodium polyacrylate, make corresponding clotrimazole gel preparation according to above-mentioned preparation technology, the final content of its mesostroma is 0.4%, and clotrimazole content is 5%.
2. method is with reference to Wu Wanying etc., the research of Radix Sophorae Flavescentis total alkaloids percutaneous rate under the different pH value, Chinese medicine journal, 1999 (2), the disclosed method of 61-62.
3 results
Group Accumulation infiltration equation (μ g/cm 2) J(μg/cm 2h) r
Carbopol 941 Q=-112.939+92.654t 92.654 0.9875
Acritamer 940 Q=-18.339+21.765t 21.765 0.9616
Carbomer 934 Q=-97.521+82.869t 82.869* 0.9876
Methylcellulose Q=-53.597+46.325t 46.325 0.9766
Sodium carboxymethyl cellulose Q=-88.199+54.756t 54.756 0.9428
Cross linked sodium polyacrylate Q=-76.130+51.968t 51.968 0.9857
Annotating 1:J is the percutaneous rate constant, the transdermal throughput of unit are in the unit interval of display-object chemical compound.
Annotate each group of 2:* and other and compare p<0.05 respectively.
This shows that the substrate of clotrimazole gel is the most excellent with carbomer 934 on the promotion Transdermal absorption.
Two, stable contrast test
Because preparation of the present invention is a semi-solid preparation, also there is the characteristic of liquid simultaneously in existing solid characteristic, so need to investigate the stability of gel preparation of the present invention.Now 6 kinds of gel preparations that obtained in the selection with gel substrate carry out light durability relatively.
Get the above-mentioned preparation of respectively organizing, Continuous irradiation 10 days respectively at sampling in 0,5,10 day, is checked its appearance character, content, the results are shown in following table.
The result is investigated in the light durability test
Group 0 day 5 days 10 days
Carbopol 941 4.75 4.24 4.01
Acritamer 940 4.49 4.21 4.00
Carbomer 934 4.84 4.78 4.27
Methylcellulose 5.02 4.45 4.12
Sodium carboxymethyl cellulose 5.07 4.34 4.04
Cross linked sodium polyacrylate 4.94 4.12 4.05
Annotate: data are clotrimazole content in the table, by weight percentage.
Use the prescription stability of carbomer 934 obviously to be better than other each group as can be known by data in the table.
Three, example of formulations
1.pH value is investigated:
Investigating carbomer and triethanolamine under the different proportion situation and pH value, is index with pH value 6-7.5, establishes
The meter test:
Figure A20061010967400081
Interpretation of result:
Carbomer and triethanolamine ratio are that 1: 1 o'clock pH value meets the requirements.
2 viscositys are investigated:
Investigate the carbomer of different amounts and triethanolamine 1: 1 o'clock viscosity size.
The design single factor experiment:
Carbomer and triethanolamine consumption Clotrimazole Glycerol Ethyl hydroxybenzoate Viscosity
3% 5% 10% 0.06% Very big preparation difficulty
2% 5% 10% 0.06% Bigger
1% 5% 10% 0.06% Suitable
0.8% 5% 10% 0.06% Less
0.6% 5% 10% 0.06% Less, flowability is arranged
0.4% 5% 10% 0.06% Very little, flowability is arranged
By above result of the test as can be known: carbomer and triethanolamine 1: 1, consumption are that to make clotrimazole gel viscosity at 1% o'clock suitable.
Comprehensive above-mentioned investigation result of the test can draw preparation prescription and adopt clotrimazole (5%), glycerol (10%), and Ka Baimu 934 (1%), triethanolamine (1%), the preparation of ethyl hydroxybenzoate (0.06%) mixture.
Preferred embodiment 1:
Clotrimazole 150g 5%
Glycerol 300g 10%
Ka Baimu 934 12g 0.4%
Ethyl hydroxybenzoate 1.5g 0.05%
Triethanolamine 15g 0.5%
Distilled water adds to 3000g in right amount to 100%
Technology:
(1) distilled water boiling sterilization takes by weighing ethyl hydroxybenzoate 1.5g, is dissolved in the 2100ml hot water (80 ℃), puts and is chilled to 40 ℃, and is standby.
(2) get carbomer 12g in addition, gradation is spread in the above-mentioned solution, is stirred to be uniformly dispersed, and leaves standstill 2h, and is standby.
(3) take by weighing triethanolamine 15g, slowly add in the above-mentioned solution with distilled water (420ml) dilution back; Add glycerol again, be stirred to translucent homogeneous system, the white gel of having leisure.
(4) take by weighing clotrimazole fine powder 150g, evenly spread in the blank gel, be stirred to homogeneous system.
(5) gel is sub-packed in the vaginal administration device, promptly.
Preferred embodiment 2:
Clotrimazole 150g 5%
Glycerol 300g 10%
Ka Baimu 934 15g 0.5%
Ethyl hydroxybenzoate 1.5g 0.05%
Triethanolamine 15g 0.5%
Distilled water adds to 3000g in right amount to 100%
Technology is with preferred embodiment 1
In sum, gel preparation of the present invention all is better than conventional the selection at aspects such as stability, Transdermal absorption, and these effects obviously are not medicine or adjuvants itself, or dosage form itself is brought.Therefore, the application's technical scheme is paid creative work than prior art.Thereby the application's technical scheme is creative.

Claims (3)

1, a kind of clotrimazole gel preparation, it comprises clotrimazole 3-5%, substrate 0.1-15%.
2, clotrimazole gel preparation as claimed in claim 1, it is composed as follows: in parts by weight
Clotrimazole 5%
Glycerol 10%
Ka Baimu 934 0.4%
Ethyl hydroxybenzoate 0.05%
Triethanolamine 0.5%
Distilled water is in right amount to 100%
Wherein:
(1) distilled water boiling sterilization takes by weighing ethyl hydroxybenzoate 1.5g, is dissolved in the 2100ml hot water (80 ℃), puts and is chilled to 40 ℃, and is standby;
(2) get carbomer 12g in addition, gradation is spread in the above-mentioned solution, is stirred to be uniformly dispersed, and leaves standstill 2h, and is standby;
(3) take by weighing triethanolamine 15g, slowly add in the above-mentioned solution with distilled water 420ml dilution back; Add glycerol again, be stirred to translucent homogeneous system, the white gel of having leisure;
(4) take by weighing clotrimazole fine powder 150g, evenly spread in the blank gel, be stirred to homogeneous system;
(5) gel is sub-packed in the vaginal administration device, promptly.
3, the preparation method of clotrimazole gel preparation as claimed in claim 1 or 2 is characterized in that: gets the various raw materials of capacity (1) distilled water boiling sterilization ready, takes by weighing ethyl hydroxybenzoate 1.5g, be dissolved in the 2100ml80 ℃ of hot water, put and be chilled to 40 ℃, and standby;
(2) get carbomer 12g in addition, gradation is spread in the above-mentioned solution, is stirred to be uniformly dispersed, and leaves standstill 2h, and is standby;
(3) take by weighing triethanolamine 15g, slowly add in the above-mentioned solution with distilled water 420ml dilution back; Add glycerol again, be stirred to translucent homogeneous system, the white gel of having leisure;
(4) take by weighing clotrimazole fine powder 150g, evenly spread in the blank gel, be stirred to homogeneous system;
(5) gel is sub-packed in the vaginal administration device, promptly.
CNB2006101096740A 2006-08-16 2006-08-16 Clotrimazole gel, and its prepn. method Expired - Fee Related CN100446753C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006101096740A CN100446753C (en) 2006-08-16 2006-08-16 Clotrimazole gel, and its prepn. method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006101096740A CN100446753C (en) 2006-08-16 2006-08-16 Clotrimazole gel, and its prepn. method

Publications (2)

Publication Number Publication Date
CN1903174A true CN1903174A (en) 2007-01-31
CN100446753C CN100446753C (en) 2008-12-31

Family

ID=37672635

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006101096740A Expired - Fee Related CN100446753C (en) 2006-08-16 2006-08-16 Clotrimazole gel, and its prepn. method

Country Status (1)

Country Link
CN (1) CN100446753C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103126974A (en) * 2011-11-30 2013-06-05 王冕 Gel
CN109431969A (en) * 2018-12-29 2019-03-08 天津凯茵科技有限公司 A kind of gynaecology's compound clotrimazole composition
CN109431968A (en) * 2018-12-29 2019-03-08 天津凯茵科技有限公司 Gynaecology's compound based on clotrimazole
WO2019134159A1 (en) * 2018-01-08 2019-07-11 刘琦 Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103126974A (en) * 2011-11-30 2013-06-05 王冕 Gel
CN103126974B (en) * 2011-11-30 2018-04-10 王冕 A kind of gel
WO2019134159A1 (en) * 2018-01-08 2019-07-11 刘琦 Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor
US11253471B2 (en) 2018-01-08 2022-02-22 Qi Liu Rectal mucosal administration preparation of Pulsatilla chinensis saponin B4 and preparation method therefor
CN109431969A (en) * 2018-12-29 2019-03-08 天津凯茵科技有限公司 A kind of gynaecology's compound clotrimazole composition
CN109431968A (en) * 2018-12-29 2019-03-08 天津凯茵科技有限公司 Gynaecology's compound based on clotrimazole

Also Published As

Publication number Publication date
CN100446753C (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CN100444847C (en) Micronize diosmin and hesperidine composition suppository
CN1903174A (en) Clotrimazole gel, and its prepn. method
CN1742938A (en) Lifukang medicine for vagina and preparing method thereof
CN1810246A (en) Nasal in-situ gel of scopolamine with phase change property
CN1903351A (en) Funing gel prepn. and its prepn. method
Małolepsza-Jarmołowska The effect of poloxamer 407 on the properties of hydrophilic gels containing lactic acid complexed with chitosan
CN1771937A (en) Externally applied podophyllotoxin ointment and its prepn
CN1850083A (en) Dispersible tablet for treating cold and its preparing process
CN104095804A (en) In-situ gel film agent with biological adhesion and preparation method thereof
CN1186336C (en) Prepn and application in preparing medicine of fraxinus general coumarin
CN109010837B (en) Celecoxib composition with high solubility
CN1699370A (en) Artesunate salt and its preparation process and use
CN103505406B (en) Nifuratel gel and preparation method thereof
CN102697703B (en) Piroxicam gel preparation and preparation method thereof
CN1771989A (en) Compound prepn for treating women's inflammation
CN1279912C (en) Use of sinomenine
CN1237967C (en) Novel use of indomethacin and its external applied preparation for treating cutaneous pruritus
CN1618427A (en) Medicinal resin biological adhering slow-releasing liquid prepn. contg. aciclovir, and its prepn. method
CN1562045A (en) Doxycycline dripping pill
CN103893109B (en) A kind of pharmaceutical composition of tropisetron
CN1309376C (en) Musk slow-controlled release preparation and preparation method thereof
CN1272000C (en) Troxerutin-coumarin dripping pill
CN1714787A (en) Tromethamine gel form medicinal composition
CN1799536A (en) Bexarotene gel and its preparation method
CN1778299A (en) Cavitas nasisal cavity medicine-supply preparation with radix aconiti agrestis methyl

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15

Patentee after: COSCI MED-TECH Co.,Ltd.

Address before: 100080, room 1410, satellite building, No. 63, Zhichun Road, Beijing, Haidian District

Patentee before: COSCI MED-TECH Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20230403

Address after: 8639, Floor 6, Building 3, No. 3, Yongchang North Road, Daxing District, Beijing, 100176

Patentee after: Beijing Kexin Jurun Pharmaceutical Technology Co.,Ltd.

Address before: 100083 room 15, 15 / F, block a, Tiangong building, 30 Xueyuan Road, Haidian District, Beijing

Patentee before: COSCI MED-TECH Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081231

CF01 Termination of patent right due to non-payment of annual fee